Introduction
Ventilator-associated pneumonia (VAP) is defined as pneumonia that develops more than 48-72 h following endotracheal intubation, and is characterized by the presence of new progressive infiltrates, signs of systemic infection (fever, altered white blood cell count, changes in sputum characteristics), and detection of a causative agent [1] . VAP, which is the commonest infection obtained in the ICU, affects 4.8-7.5% of patients intubated for more than 24 h [2] and is accompanied with greater morbidity and mortality [3] .
In developing countries, patients with VAP infections had total costs of nearly fivefold higher than those of other patients [4] . Application of preventive strategies has lowered the excess risk of death which is recently estimated at 9-13% [5] . Treatment of VAP accounts approximately for half of all antimicrobials received in ICUs.
Early-onset VAP is defined as pneumonia that develops within 72 h and this is usually attributed to antibiotic-sensitive pathogens, whereas late-onset VAP is more likely associated with multidrug resistant (MDR) bacteria and occurs after 4 days of intubation [6] . Among mechanically ventilated patients, it was noted that 80% of cases of pneumonia involve Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella spp., Acinetobacter spp., and/or Enterobacter spp.
Other pathogens, including Serratia
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spp., Streptococcus pneumoniae, and Haemophilus influenzae, may also be involved [7] . Fosfomycin, which is a phosphonic acid was discovered in 1969 [8] . It has a valuable advantage regarding its action, as it inactivates the enzyme pyruvyl-transferase needed to synthesize the bacterial cell wall peptidoglycan, escaping cross-resistance with other classes of antibiotics [9] . Fosfomycin entails activity against both Grampositive and Gram-negative pathogens. It is always used in combination with other antimicrobial agents, owing to the development of resistance it is rapid when received as monotherapy. It has been coadministered mostly with aminoglycosides, namely tobramycin for the management of chronic endobronchial infections due to Pseudomonas and methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis [10] .
The current study was designed to evaluate the effectiveness of fosfomycin administration in patients with VAP.
Patients and methods
The present trial was held in Respiratory Intensive Care Unit and Poison Centre in Ain Shams University Hospitals, Egypt. A randomized, controlled trial was designed between November 2015 and April 2016 including 40 patients diagnosed with VAP. Patients were classified into two groups: group A (control group) included patients receiving only empirical systemic antibiotics (according to suspected organism and general condition of the patient) and group B included patients receiving oral fosfomycin combined with empirical systemic antibiotics.
All patients selected in the study had been subjected to the following:
(1) Full medical history including age, sex, cause, and duration of mechanical ventilation and comorbid diseases. including arterial blood gas, complete blood count, serum creatinine, liver function test, Na, K, and Creactive protein (CRP). (4) The endotracheal tube aspirates were collected using 14-inch or 12-inch suction catheter attached to a mucus extractor. (5) VAP was diagnosed based on the clinical criteria using the modified-clinical pulmonary infection score (CPIS) score designed by Pugin and others, giving 0-2 points each for fever, leukocyte count, oxygenation status, quantity and purulence of tracheal secretions, type of radiographic abnormality, and result of sputum culture and Gram stain [11] . (6) Group B received fosfomycin tromethamine sachet (containing 5.631 g of fosfomycin tromethamine − equivalent to 3 g of fosfomycin). The powder in the sachet was taken immediately after dissolution into 90-120 ml of water. (7) Patients were closely observed, the CPIS score was calculated before the start of antibiotics, then once more on day 5 in order to monitor efficacy of the antibiotics used.
Efficacy endpoints
The primary end point was the modification from baseline CPIS during the planned 14 days treatment period. Secondary endpoints included mortality and time to clinical cure (defined as no fever, normal chest examination, negative culture, or no sputum available to culture in an extubated patient at day 14 or earlier).
Statistical analysis
Data were recorded, and analyzed by the statistical package for the social sciences (IBM SPSS) version 20.
Qualitative variables were expressed as number and percentages whereas quantitative normally distributed variables were presented as mean, SD. χ 2 -Test and/or Fisher's exact test was used to compare between two groups with qualitative data. The comparison between two groups with quantitative data was done by using Student's t-test. Correlation between two quantitative parameters was done by the Pearson correlation. The P value was considered significant if P value of less than 0.05.
Results
The current study consisted of two comparable groups diagnosed with VAP. Mean treatment duration was significantly lower in group B compared with group A (9.45 vs. 16 .67 days, respectively, P<0.05). Both groups showed matching in age and sex. Women were noted to be the majority among the studied patients in both groups ( Table 1 ). The majority of patients in groups A and B were diagnosed as having early-onset pneumonia 75 and 70%, respectively, whereas late-onset pneumonia accounted for 25% in group A compared with 30% in group B without significant difference.
Klebsiella pneumoniae was the most prevalent organism in cases of early as well as late-onset pneumonia (34.4 and 36%, respectively). Incidence of MDR Acinobacter was higher in late-onset pneumonia (45%); however, it was not uncommon in early-onset pneumonia (27%). P. aeruginosa was isolated only in early-onset pneumonia (20%) compared with 35% in late-onset pneumonia.
Other less common species like S. pneumoniae and Staphylococcus aureus were also isolated.
CPIS was considered the primary end point in the present study. Before start of therapy, this score was elevated in both study groups (P=0.612). At fifth day of follow-up, CPIS was calculated again and a significant decline was noted in group B, while it remains higher in group A (6.13 vs. 5.15, respectively, P=0.004). CRP was also evaluated as a marker of bacterial infection used to assess response of therapy. It was highly increased in both groups being more in group A in comparison to the other group. On the fifth day, CRP was significantly decreased in group B (P=0.019), although it did not show any significant decline in group A (P=0.079) ( Table 2) .
Mortality rate was another predictor of successful therapy among patients in both groups, where five (25%) patients in group B versus eight (40%) in group A had died during the period of follow-up (P=0.082). Fifteen (75%) patients in group B had showed complete cure (no fever − negative culture) compared with 60% in group A (P=0.208).
The correlation between age and CPIS revealed a significant relationship between both variables in both the study groups; on the other hand, no significant difference existed between CPIS and sex in both groups even if CPIS was slightly elevated in men of group A at day 5 of follow-up.
Kaplan-Meier analysis reveals an estimated 14-day survival of 60 and 75% (P=0.208) in group A (systemic antibiotics only) and group B (fosfomycin and systemic antibiotics), respectively.
Discussion
Fosfomycin is an antibiotic that produces bactericidal action against several Gram-negative and Grampositive pathogens. This agent displays few side effects. Unfortunately when used as monotherapy, fosfomycin exhibits rapid resistance. Owing to the synergistic action of fosfomycin with other antimicrobials, it is an interesting treatment of choice for multiple infections, including VAP caused by MDR organisms [12] (Table 3 and 4, Figs. 1-3 ).
This antimicrobial agent has recently obtained effectiveness in treating extensively resistant Gramnegative bacilli especially K. pneumoniae or P. aeruginosa as well as Enterobacteriaceae owing to the shortage of other valid agents. A recent study has demonstrated successful response in patients with VAP treated with high doses (24 g/day) of fosfomycin always in combination with other antimicrobials [13] . In a Greek study, fosfomycin successfully eradicated in vitro 91.8% of extensively drug-resistant Enterobacteriaceae [12] . In spite of the in-vitro efficacy of fosfomycin, clinical practice had shown limited action to non-MDR infections, and thus has led to decreased clinical outcomes which is reported to be greater than 80% [14] .
Dinh et al. [15] presented a study with 116 patients complaining of MDR infections, mostly caused by Staphylococcus spp. and Pseudomonas spp. The overall success rate was achieved in 76.8%, despite specific bias mostly methodological that limits generalizability of the results [15] .
In Greece, a small clinical trial was published, 11 patients presented in the ICU treated with fosfomycin combinations against carbapenemaseproducing K. pneumonia; however, no certain conclusions could be achieved due to the Cohort's small size [16] . A total 49 patients were included in another retrospective study. They suffered from VAP or nosocomial pneumonia mostly due to P. aeruginosa with moderate resistance to carbapenems. Fosfomycin disodium was added to either high-dose doripenem or colistin. Insignificant differences were noted among groups concerning clinical recovery (60 vs. 58%), microbiological eradication (72 vs. 75%), and allcause mortality (40 vs. 42%) [17] .
Early-onset pneumonia was presented in 75 and 70% of patients in groups A and B respectively. Hina et al. came to different results as early-onset VAP was found in 27.02% [18] . Furthermore, another study it was reported to be around 40% [19] .
A recent study has shown CPIS improvement from baseline without difference between groups. Mean CPIS at day 10 were 5.0 for the amikacin fosfomycin inhalation system arm compared with 4.8 in the other placebo arm (P=0.81). In a pre-hoc analysis, no differences in CPIS outcomes were noted in subgroups of age, baseline Apache score, and sex [20] . Different findings existed in our study as we reported significant correlation between age and CPIS in both study groups; on the other hand, no significant difference existed between CPIS and sex in both groups. This could be attributed to the different days of measurement evaluation.
Kollef et al. [20] reported that mortality through day 28 was 24% in the amikacin fosfomycin inhalation system group (n=17) and 17% in the placebo group (n=12). Interestingly, in our study mortality rate (25%) was nearly similar to the previous study [20] .
Strengths and limitations of the study
The power of this trial is referred to the presence of comparable groups as well as its variability, because fosfomycin was used against several infections. Additionally, it reported a 'real world' demostration Comparison between groups A and B regarding clinical pulmonary infection score on day 1 and day 5. CPIS, clinical pulmonary infection score.
Figure 2
Comparison between groups A and B regarding C-reactive protein on day 1 and day 5. CRP, C-reactive protein.
Figure 3
The Kaplan-Meier curve of group A versus group B.
of efficacy in severely ill, septic ICU patients, which is appreciable pending the outcome of controlled trials. Furthermore, there were other limitations in this study which were attributed to the small-sized groups, as well as the study was not blinded.
Conclusion
The predominance of Gram-negative bacteria supports the fact that VAP occurs by bacterial colonization of the aerodigestive tract and subsequent aspiration. Fosfomycin is an effective antimicrobial agent in the treatment of VAP with low mortality rate. Furthermore, CPIS is a potential score used to evaluate the effectiveness of therapy in cases of VAP.
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